CAI - NASDAQ
Caris Life Sciences, Inc.
$15.48
-1.5%Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.
At a Glance
Live SnapshotCaris Life Sciences, Inc. Management Team
Dr. David Dean Halbert M.D.
Chairman, Chief Executive Officer & Founder
Compensation
$2,250,000
Mr. Brian J. Brille J.D.
Executive Vice Chairman & Executive Vice President
Compensation
$1,200,000
Dr. David Spetzler M.B.A., M.S., MBA, MS, Ph.D.
President
Compensation
$1,213,800
Mr. Jon Mark Harmon
Senior Vice President & Chief Operations Officer
Dr. Milan Radovich Ph.D.
Senior Vice President & Chief Scientific Officer
Dr. Valeriy Domenyuk
Senior Vice President & Chief Technology Officer
Mr. Narendra Chokshi
Senior Vice President of Corporate Development
Mr. Luke Power
Senior Vice President, Chief Financial Officer & Chief Accounting Officer
Ms. Ginger Appleberry J.D.
Senior Vice President, Deputy General Counsel & Chief Compliance Officer
Mr. J. Russel Denton
Senior Vice President, General Counsel & Secretary
Caris Life Sciences, Inc. Insider Positioning
During the last 12 months, insiders have purchased $612K and sold $1.62M worth of CAI shares, resulting in $1.00M of net selling activity.
3 Months
31.1K
501.43K
0
0.00
+501K
+$501K
3-6 Months
0
0.00
60.9K
1.62M
-1.6M
-$1.62M
6-9 Months
4.6K
110.33K
0
0.00
+110K
+$110K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Vacirca Jeff L
Director
$501K
Denton John Russel
Officer: See Remarks
$101K
Spetzler David Baxley
Officer: President
$10K
Top Sellers
Power Luke Thomas
Officer: See Remarks
$1.62M
Insider Activity Analysis
Net Insider Sentiment
Negative insider sentiment with $1.00M net selling. Selling notably exceeds buying, warranting closer scrutiny of company fundamentals.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Recent Trend (3 Months)
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
Insider Participation
3 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
SEC Filings
CAI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 04, 2026 | 2026 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.